Table 2.
Multivariate model of baseline demographic and clinical variables as predictors of response to anti-TNF treatment at 6 months.
| Baseline variables | Coefficient (P value) |
|---|---|
| Age (years) | −0.01 (0.25) |
| Disease duration (years) | 0.01 (0.24) |
| Female gender | −0.01 (0.95) |
| ACPA (positive) | −0.07 (0.64) |
| Smoking (ever) | −0.06 (0.72) |
| Higher education (years) | 0.03 (0.03)* |
| Corticosteroids (yes) | −0.16 (0.26) |
| DMARDs (yes) | 0.05 (0.83) |
| Extra-artic. manif. (yes) | 0.10 (0.49) |
| HAQ | −0.40 (0.002)* |
| PhGA (mm) | −0.001 (0.68) |
| DAS | 0.60 (<0.001)* |
* P value <0.05.
The probability of response to anti-tumor necrosis factor therapy at 6 months was modeled in a multivariate linear regression analysis.
The change in disease activity score assessing 28 joints between the baseline visit and the visit after 6 months of therapy was the continuous outcome.
ACPA: anticitrullinated peptides antibodies; DMARDs: disease modifying antirheumatic drugs; Extra-artic. manif.: extra-articular manifestations; HAQ: Health Assessment Questionnaire; PhGA: physician global assessment; DAS: disease activity score.